Sodium (R)-2-(4’-(3-Methyl-4-(((1-Phenylethoxy)Carbonyl)Amino)Isoxazol-5-Yl)-[1,1’-Biphenyl]-4-Yl)Acetate (R)-2-(4’-(3-甲基-4-(((1-苯基乙氧基)羰基)氨基)异噁唑-5-基)-[1,1’-联苯]-4-基)乙酸钠
CAS 1345614-59-6 MFCD445614596
化学结构图
SMILES:
化学属性
| Mol. Formula | C27H24N2O5.Na |
|---|
别名和识别编码
| Chemical Name | Sodium (R)-2-(4’-(3-Methyl-4-(((1-Phenylethoxy)Carbonyl)Amino)Isoxazol-5-Yl)-[1,1’-Biphenyl]-4-Yl)Acetate |
|---|---|
| Chemical Name Translation | (R)-2-(4’-(3-甲基-4-(((1-苯基乙氧基)羰基)氨基)异噁唑-5-基)-[1,1’-联苯]-4-基)乙酸钠 |
| Chemicalbook ID | CB52627312 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
相关文献及参考
- [2]. Castelino FV, et al. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum. 2011 May;63(5):1405-15.
- [1]. Swaney JS, et al. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J Pharmacol Exp Ther. 2011 Mar;336(3):693-700.
- [1]. Swaney JS, et al. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J Pharmacol Exp Ther. 2011 Mar;336(3):693-700.
- [2]. Castelino FV, et al. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum. 2011 May;63(5):1405-15.
